{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T15:16:28Z","timestamp":1783350988068,"version":"3.54.6"},"reference-count":19,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,9,1]],"date-time":"2016-09-01T00:00:00Z","timestamp":1472688000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","lungcancerjournal.info","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Lung Cancer"],"published-print":{"date-parts":[[2016,9]]},"DOI":"10.1016\/j.lungcan.2016.06.026","type":"journal-article","created":{"date-parts":[[2016,7,3]],"date-time":"2016-07-03T03:47:18Z","timestamp":1467517638000},"page":"123-126","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":47,"special_numbering":"C","title":["Severe agranulocytosis in a patient with metastatic non-small-cell lung cancer treated with nivolumab"],"prefix":"10.1016","volume":"99","author":[{"given":"Samer","family":"Tabchi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoduan","family":"Weng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Normand","family":"Blais","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.lungcan.2016.06.026_bib0005","doi-asserted-by":"crossref","DOI":"10.1002\/cam4.732","article-title":"Targeting immune checkpoints in unresectable metastatic cutaneous melanoma: a systematic review and meta-analysis of anti-CTLA-4 and anti-PD-1 agents trials","author":"Yun","year":"2016","journal-title":"Cancer Med."},{"issue":"8","key":"10.1016\/j.lungcan.2016.06.026_bib0010","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved survival with ipilimumab in patients with metastatic melanoma","volume":"363","author":"Hodi","year":"2010","journal-title":"N. Engl. J. Med."},{"issue":"17","key":"10.1016\/j.lungcan.2016.06.026_bib0015","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1056\/NEJMoa1507643","article-title":"Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer","volume":"373","author":"Borghaei","year":"2015","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.lungcan.2016.06.026_bib0020","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1056\/NEJMoa1504627","article-title":"Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer","volume":"373","author":"Brahmer","year":"2015","journal-title":"New Engl. J. Med."},{"key":"10.1016\/j.lungcan.2016.06.026_bib0025","article-title":"Rare side-effects of checkpoint inhibitors","author":"Kourie","year":"2016","journal-title":"Curr. Opin. Oncol."},{"issue":"1","key":"10.1016\/j.lungcan.2016.06.026_bib0030","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1097\/MOH.0b013e3282f15fb9","article-title":"Idiosyncratic drug-induced agranulocytosis or acute neutropenia","volume":"15","author":"Andres","year":"2008","journal-title":"Curr. Opin. Hematol."},{"issue":"11","key":"10.1016\/j.lungcan.2016.06.026_bib0035","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1097\/SMJ.0b013e3181f46647","article-title":"Asacol\u00ae-induced neutropenia resolution without the use of granulocyte colony-stimulating factor","volume":"103","author":"Fowler","year":"2010","journal-title":"South Med. J."},{"issue":"3","key":"10.1016\/j.lungcan.2016.06.026_bib0040","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1179\/1607845412Y.0000000043","article-title":"Pure white cell aplasia induced by mesalazine in a patient with ulcerative colitis","volume":"18","author":"Frattini","year":"2013","journal-title":"Hematology"},{"issue":"9","key":"10.1016\/j.lungcan.2016.06.026_bib0045","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1002\/cncr.27969","article-title":"Patterns of onset and resolution of immune-related adverse events of special interest with ipilimumab: detailed safety analysis from a phase 3 trial in patients with advanced melanoma","volume":"119","author":"Weber","year":"2013","journal-title":"Cancer"},{"key":"10.1016\/j.lungcan.2016.06.026_bib0050","series-title":"Safety Profile of Nivolumab (NIVO) in Patients (pts) with Advanced Melanoma (MEL): A Pooled Analysis","author":"Weber","year":"2015"},{"issue":"2","key":"10.1016\/j.lungcan.2016.06.026_bib0055","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1056\/NEJMoa1305133","article-title":"Safety and tumor responses with lambrolizumab (anti\u2013PD-1) in melanoma","volume":"369","author":"Hamid","year":"2013","journal-title":"New Engl. J. Med."},{"issue":"10","key":"10.1016\/j.lungcan.2016.06.026_bib0060","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1200\/JCO.2013.53.0105","article-title":"Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab","volume":"32","author":"Topalian","year":"2014","journal-title":"J. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.lungcan.2016.06.026_bib0065","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1097\/CJI.0b013e31819aa40b","article-title":"Neutropenia in a patient treated with ipilimumab (anti-CTLA-4 antibody)","volume":"32","author":"Akhtari","year":"2009","journal-title":"J. Immunother."},{"issue":"5","key":"10.1016\/j.lungcan.2016.06.026_bib0070","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1016\/j.trsl.2015.06.005","article-title":"Immune-mediated adverse events of anticytotoxic T lymphocyte-associated antigen 4 antibody therapy in metastatic melanoma","volume":"166","author":"Quirk","year":"2015","journal-title":"Transl. Res."},{"issue":"12","key":"10.1016\/j.lungcan.2016.06.026_bib0075","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1016\/j.autrev.2013.07.002","article-title":"CTLA-4 and autoimmunity: new insights into the dual regulator of tolerance","volume":"12","author":"Romo-Tena","year":"2013","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.lungcan.2016.06.026_bib0080","doi-asserted-by":"crossref","first-page":"534","DOI":"10.5604\/17322693.1150784","article-title":"[The role of the PD-1 protein in pathogenesis of autoimmune diseases, with particular consideration of rheumatoid arthritis and systemic lupus erythematosus]","volume":"69","author":"Siwiec","year":"2015","journal-title":"Postepy higieny i medycyny doswiadczalnej (Online)"},{"issue":"2","key":"10.1016\/j.lungcan.2016.06.026_bib0085","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1001\/jamaoncol.2015.4368","article-title":"Ipilimumab therapy in patients with advanced melanoma and preexisting autoimmune disorders","volume":"2","author":"Johnson","year":"2016","journal-title":"JAMA Oncol."},{"issue":"1","key":"10.1016\/j.lungcan.2016.06.026_bib0090","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1080\/23809000.2016.1142827","article-title":"The management of immune-related adverse events associated with immune checkpoint blockade","volume":"1","author":"Fay","year":"2016","journal-title":"Expert Rev. Qual. Life Cancer Care"},{"issue":"28","key":"10.1016\/j.lungcan.2016.06.026_bib0095","doi-asserted-by":"crossref","first-page":"3193","DOI":"10.1200\/JCO.2015.60.8448","article-title":"Immune-Related adverse events, need for systemic immunosuppression, and effects on survival and time to treatment failure in patients with melanoma treated with ipilimumab at memorial sloan kettering cancer center","volume":"33","author":"Horvat","year":"2015","journal-title":"J. Clin. Oncol."}],"container-title":["Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500216303956?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500216303956?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,10]],"date-time":"2018-09-10T19:52:26Z","timestamp":1536609146000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169500216303956"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,9]]},"references-count":19,"alternative-id":["S0169500216303956"],"URL":"https:\/\/doi.org\/10.1016\/j.lungcan.2016.06.026","relation":{},"ISSN":["0169-5002"],"issn-type":[{"value":"0169-5002","type":"print"}],"subject":[],"published":{"date-parts":[[2016,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Severe agranulocytosis in a patient with metastatic non-small-cell lung cancer treated with nivolumab","name":"articletitle","label":"Article Title"},{"value":"Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lungcan.2016.06.026","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Ireland Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}